Harrow Health Inc is trading at $39.65 (up 5.3%) as the U.S. relaunch of its VERKAZIA ophthalmic treatment continues to fuel a sharp multi-day advance.
- Recent news coverage highlights renewed investor optimism regarding the commercial potential of VERKAZIA for vernal keratoconjunctivitis as the primary driver of the stock's outperformance.
- While the move coincides with a broader market rally, the specific product relaunch remains the key catalyst for the stock's gains over the past several sessions.